Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial

OBJECTIVE: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between obje...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Liver Cancer
Asıl Yazarlar: Kudo, Masatoshi, Ueshima, Kazuomi, Chiba, Yasutaka, Ogasawara, Sadahisa, Obi, Shuntaro, Izumi, Namiki, Aikata, Hiroshi, Nagano, Hiroaki, Hatano, Etsuro, Sasaki, Yutaka, Hino, Keisuke, Kumada, Takashi, Yamamoto, Kazuhide, Imai, Yasuharu, Iwadou, Shouta, Ogawa, Chikara, Okusaka, Takuji, Kanai, Fumihiko, Arai, Yasuaki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: S. Karger AG 2019
Konular:
Original Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883462/
https://ncbi.nlm.nih.gov/pubmed/31799207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503032
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller